Cardiac Sympathetic Denervation As Adjuvant Treatment To Prevent Malignant Arrhythmias In Pediatric Population.

Rossi L. (1), Cesar S. (1), Fiol V. (1), Campuzano O. (2), Tarrado X. (1), Brugada J. (1), Sarquella-Brugada G. (1,2)
(1) Arrhythmia and Sudden Death Unit, Hospital Sant Joan de Déu, Barcelona, Spain;
(2) Medical Sciences Department, School of Medicine, Cardiovascular Genetic Center, IDIBGI, Univierisity of Girona, Spain

Background: Cardiac sympathetic denervation (CSD) is a second-line treatment for adrenaline-sensitive channelopathies refractory to drugs.

Objective: Present our series of pediatric CSD for LQTS and CPVT as an adjuvant treatment to medication.

Methods: Between 2011-2018, 30 CSD (28 left, 2 right) were performed in 28 patients (21 LQTS and 7 CPVT, 26 genetically confirmed), aged 8 days-21y. Mean follow-up was 29 months. All were pharmacologically treated prior to surgery, 3 already had ICD. Indications for CSD in CPVT patients were prior cardiac arrest (3/7) and exertion or emotion-induced sustained VT despite medication (4/7). In LQTS, indications included syncope (4/21), VT despite medication (7/21), and high-risk of malignant arrhythmias (10/21) due to medication intolerance or noncompliance, family history of multiple sudden deaths, or T-wave alternation with QRS>650ms. CSD was performed via video-thoracoscopy in all; concomitant right sympatholysis was performed in 4 cases due to severe bilateral palmar hyperhidrosis.

Results: There have been neither intraoperative complications nor deaths. 4 patients had transient palpebral ptosis with mild miosis. Following CSD, 23/28 patients have been continuously monitored via ICD or ILR. After CSD, the vast majority (24/28) have been asymptomatic; three patients experienced syncope and one received an ICD appropriate shock. 7 had VT (3/7 for pharmacologic noncompliance), of which, 3 required an ICD and four improved with medication. 2 other had sporadic non-sustained VT. At f-up, 5 high-risk patients received ICDs in primary prevention due to personal decision, but none have received shocks so far. 1 LQT7 patient with asymptomatic high-density ventricular arrhythmias has not improved at all despite multiple drug combinations and CSD.

Conclusion: CSD is, in experienced hands, an effective and safe technique in children as an adjuvant treatment for severe arrhythmias due to channelopathies. Following CSD, 85% of patients remain asymptomatic. Medication non-compliance is a prominent cause of post-CSD VT, though an ICD is occasionally required despite good compliance and CSD. In our experience, long-term remote monitoring is key for effective follow-up.